Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy

@article{Lima2007ContinuedII,
  title={Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy},
  author={Viviane D. Lima and Robert S. Hogg and P. Richard Harrigan and David M. Moore and Benita Yip and Evan Wood and Julio S. G. Montaner},
  journal={AIDS},
  year={2007},
  volume={21},
  pages={685–692}
}
Objective: To characterize the temporal changes in mortality and life expectancy among HIV-positive individuals initiating antiretroviral therapy in British Columbia, Canada, from 1993 to 2004. Methods: This analysis was restricted to 2238 antiretroviral-naive HIV-positive individuals who started antiretroviral therapy between January 1993 and September 2004. The primary analysis endpoint was all-cause mortality stratified by four time periods: 1993–1995, 1996–1998, 1999–2001, and 2002–2004… 
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
TLDR
Life expectancy in HIV-infected patients treated with combination antiretroviral therapy increased between 1996 and 2005, although there is considerable variability between subgroups of patients.
Mortality Risk After AIDS-Defining Opportunistic Illness Among HIV-Infected Persons--San Francisco, 1981-2012.
TLDR
Survival after first AIDS-OI diagnosis has improved markedly since 1981, but some AIDS- OIs remain associated with substantially higher mortality risk than others, even after adjustment for known confounders.
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals
TLDR
The life expectancy of asymptomatic HIV-infected patients who are still treatment-naive and have not experienced a CDC-B or C event at 24 weeks after diagnosis approaches that of non- Infected individuals, however, follow-up time is short compared to the expected number of years lived.
Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada
TLDR
Life expectancy and mortality for HIV-positive individuals receiving ART differ by calendar period and patient characteristics at treatment initiation, and failure to consider LTFU may result in underestimation of mortality rates and overestimation of life expectancy.
Improved Survival in HIV Treatment Programmes in Asia
TLDR
The results suggest that HIV-positive patients from Asia have improved survival in more recent years of ART initiation, likely a consequence of improvements in treatment, patient management and monitoring over time.
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals
TLDR
It is estimated that cART halved the average mortality rate in HIV-infected individuals and was greater in those with worse prognosis at the start of follow-up.
Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study
TLDR
Although the rate of ADCs continues to fall, the rates of NADCs is rising and now accounts for the majority of cancers in HIV-infected persons.
Life Expectancy of Persons Receiving Combination Antiretroviral Therapy in Low-Income Countries: A Cohort Analysis From Uganda
TLDR
Ugandan patients receiving cART can expect an almost normal life expectancy, although there is considerable variability among subgroups of patients.
Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
TLDR
A 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population.
Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study
TLDR
Trends in reported ADIs among individuals receiving highly active antiretroviral therapy (HAART) in British Columbia (BC), Canada do not appear to parallel improvements in life-expectancy over the same period.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up
TLDR
It is demonstrated that even after adjusting for other prognostic factors intermittent use of antiretroviral therapy was associated with increased mortality, and that those participants who used antireTroviral drugs intermittently were more likely to die.
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.
TLDR
The HIV-infected individuals who receivedInitial therapy with regimens including stavudine or lamivudine had significantly lower mortality and longer AIDS-free survival than those who received initial therapy withregimens limited to zidovudine, didanosine, and zalcitabine.
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
TLDR
The initial drop in mortality and morbidity after the introduction of HAART has been sustained and potential long-term adverse effects associated with HAART have not altered its effectiveness in treating AIDS.
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study
TLDR
The introduction of antiretroviral combination therapies outside the selected patient groups included in clinical trials has led to comparable reductions in disease progression and mortality in Switzerland.
The survival benefits of AIDS treatment in the United States.
TLDR
At least 3.0 million years of life have been saved in the United States as a direct result of care of patients with AIDS, highlighting the significant advances made in HIV disease treatment.
Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART
TLDR
It is demonstrated that emergence of resistance to non-nucleoside reverse transcriptase inhibitors was associated with a greater risk of subsequent death than was emergence of protease inhibitor resistance.
Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia
TLDR
There are substantial disparities in life expectancy for persons living with HIV in British Columbia, and members of the injection drug community, particularly those who are not taking HAART, experience elevated mortality in comparison with those without a history of drug use.
Decline in deaths from AIDS due to new antiretrovirals
TLDR
There was a significant decline in programme mortality rates since the first quarter of 1994, and this decline coincides with the availability of lamivudine in the province through open access and with the expanded use of double combination antiretroviral therapy.
Natural history of HIV infection in the era of combination antiretroviral therapy.
TLDR
A significant decline in the incidence of opportunistic illness and death from 1994 through 1998 associated with combination antiretroviral therapy was observed and the concurrent CD4 level was most strongly associated with developing an event.
Declining AIDS Mortality in Amsterdam: Contributions of Declining HIV Incidence and Effective Therapy
TLDR
The decline in AIDS mortality was the result of both HAART and a decline in the HIV incidence in the early 1980s, and it is estimated that 331 deaths among homosexual men were prevented by HAART between 1996 and 2000 in Amsterdam.
...
1
2
3
4
5
...